BMS' Opdivo gets green light for UK early access scheme
This article was originally published in Scrip
Executive Summary
In what appears to be only the second such decision by the UK regulator, the MHRA, Bristol-Myers Squibb's advanced melanoma product Opdivo (nivolumab) has been given the go-ahead to enter the Early Access to Medicines Scheme (EAMS), meaning it can be made available in advance of its EU approval.